Koers Stellar Biotechnologies Inc Toronto S.E.
Aandelen
KLH
CA85855A2039
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 14,76 mln. 20,32 mln. 13,72 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -8 mln. -11,01 mln. -7,43 mln. | Nettowinst (verlies) 2025 * | -10 mln. -13,76 mln. -9,29 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-2,35
x | K/w-verhouding 2025 * |
-2,76
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 66,08% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Pardeep Nijhawan
FOU | Founder | 53 | 12-06-07 |
Michael Brooks
PSD | President | 46 | 01-09-15 |
Stephen Lemieux
DFI | Director of Finance/CFO | 48 | 15-07-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Sean MacDonald
BRD | Director/Board Member | 47 | 07-06-19 |
Frank Oakes
BRD | Director/Board Member | 73 | 09-04-10 |
Patrick Marshall
BRD | Director/Board Member | 53 | 23-05-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+18,72% | 125 mld. | |
+14,19% | 108 mld. | |
-4,93% | 24,21 mld. | |
+2,47% | 22,78 mld. | |
-10,65% | 17,96 mld. | |
-41,74% | 16,43 mld. | |
-13,31% | 16,37 mld. | |
+2,44% | 13,58 mld. | |
+27,89% | 11,66 mld. |